Blueprint Medicines (BPMC) Reports Q1 Loss, Lags Revenue Estimates

Blueprint Medicines (BPMC) came out with a quarterly loss of $0.74 per share versus the Zacks Consensus Estimate of a loss of$ 0.42. This compares to loss of $1.32 per share a year ago. These figures are adjusted for non-recurring items.This quarterly report represents an earnings surprise of -76.19%. A quarter ago, it was expected that this cancer drug developer would post a loss of$ 0.70 per share when it actually produced a loss of $0.79, delivering a surprise of -12.86%.Over the last four quarters, the ...